CRISPR Therapeutics AG Revenue 2015-2021 | CRSP

CRISPR Therapeutics AG annual/quarterly revenue history and growth rate from 2015 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • CRISPR Therapeutics AG revenue for the quarter ending June 30, 2021 was $0.901B, a 2046947.73% increase year-over-year.
  • CRISPR Therapeutics AG revenue for the twelve months ending June 30, 2021 was $0.902B, a 211.87% increase year-over-year.
  • CRISPR Therapeutics AG annual revenue for 2020 was $0.001B, a 99.75% decline from 2019.
  • CRISPR Therapeutics AG annual revenue for 2019 was $0.29B, a 9169.85% increase from 2018.
  • CRISPR Therapeutics AG annual revenue for 2018 was $0.003B, a 92.38% decline from 2017.
CRISPR Therapeutics AG Annual Revenue
(Millions of US $)
2020 $1
2019 $290
2018 $3
2017 $41
2016 $5
2015 $0
2014 $
CRISPR Therapeutics AG Quarterly Revenue
(Millions of US $)
2021-06-30 $901
2021-03-31 $1
2020-12-31 $0
2020-09-30 $0
2020-06-30 $0
2020-03-31 $0
2019-12-31 $77
2019-09-30 $212
2019-06-30 $0
2019-03-31 $0
2018-12-31 $0
2018-09-30 $1
2018-06-30 $1
2018-03-31 $1
2017-12-31 $32
2017-09-30 $2
2017-06-30 $4
2017-03-31 $3
2016-12-31 $2
2016-09-30 $2
2016-06-30
2016-03-31 $0
2015-12-31
2015-09-30
2014-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $7.392B $0.001B
CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00